CY1124967T1 - Παραγωγα αμινοπυριδινης και χρηση αυτων ως εκλεκτικοι αναστολεις alk-2 - Google Patents
Παραγωγα αμινοπυριδινης και χρηση αυτων ως εκλεκτικοι αναστολεις alk-2Info
- Publication number
- CY1124967T1 CY1124967T1 CY20211101137T CY211101137T CY1124967T1 CY 1124967 T1 CY1124967 T1 CY 1124967T1 CY 20211101137 T CY20211101137 T CY 20211101137T CY 211101137 T CY211101137 T CY 211101137T CY 1124967 T1 CY1124967 T1 CY 1124967T1
- Authority
- CY
- Cyprus
- Prior art keywords
- alk
- selective inhibitors
- aminopyridine derivatives
- compound
- aminopyridine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Η εφεύρεση αφορά σε μία ένωση του τύπου (Ι) σε ελεύθερη μορφή ή σε μορφή φαρμακευτικώς αποδεκτού άλατος (Ι), σε φαρμακευτικές συνθέσεις που περιλαμβάνουν την εν λόγω ένωση και στη χρήση της εν λόγω ένωσης στη θεραπεία ετεροτοπικής οστεοποίησης και προοδευτικής οστεοποιού ινοδυσπλασίας.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662364620P | 2016-07-20 | 2016-07-20 | |
PCT/CN2017/093385 WO2018014829A1 (en) | 2016-07-20 | 2017-07-18 | Aminopyridine derivatives and their use as selective alk-2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124967T1 true CY1124967T1 (el) | 2023-01-05 |
Family
ID=60991950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20211101137T CY1124967T1 (el) | 2016-07-20 | 2021-12-29 | Παραγωγα αμινοπυριδινης και χρηση αυτων ως εκλεκτικοι αναστολεις alk-2 |
Country Status (25)
Country | Link |
---|---|
US (3) | US10710980B2 (el) |
EP (2) | EP3971177A1 (el) |
JP (3) | JP7030776B2 (el) |
KR (5) | KR102454129B1 (el) |
CN (2) | CN114014844A (el) |
AR (1) | AR109108A1 (el) |
AU (4) | AU2017298187B2 (el) |
BR (1) | BR112019000941A2 (el) |
CA (1) | CA3030332A1 (el) |
CY (1) | CY1124967T1 (el) |
DK (1) | DK3487851T3 (el) |
EA (2) | EA037520B1 (el) |
ES (1) | ES2902521T3 (el) |
HR (1) | HRP20211868T1 (el) |
HU (1) | HUE057328T2 (el) |
LT (1) | LT3487851T (el) |
MX (2) | MX2019000837A (el) |
PL (1) | PL3487851T3 (el) |
PT (1) | PT3487851T (el) |
RS (1) | RS62819B1 (el) |
RU (1) | RU2747318C2 (el) |
SI (1) | SI3487851T1 (el) |
TW (4) | TWI755255B (el) |
UY (1) | UY37331A (el) |
WO (1) | WO2018014829A1 (el) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA037520B1 (ru) * | 2016-07-20 | 2021-04-07 | Новартис Аг | Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2 |
EP4061367A1 (en) * | 2019-11-22 | 2022-09-28 | Incyte Corporation | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor |
CN111170893B (zh) * | 2020-01-19 | 2022-04-26 | 郑州依米花手性药物研究有限公司 | Lefamulin的中间体化合物及其在Lefamulin制备中的应用 |
WO2021257532A1 (en) | 2020-06-16 | 2021-12-23 | Incyte Corporation | Alk2 inhibitors for the treatment of anemia |
WO2023198114A1 (zh) * | 2022-04-13 | 2023-10-19 | 杭州邦顺制药有限公司 | Alk2激酶抑制剂 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5077290A (en) | 1990-10-11 | 1991-12-31 | Merck & Co., Inc. | Morpholine derivatives compositions and use |
JP3362151B2 (ja) | 1992-11-17 | 2003-01-07 | ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ | アクチビンレセプター状キナーゼ活性を有するタンパク質をコードする単離核酸分子、及び、これを用いた発現ベクタ、組み換え細胞、単離タンパク質、単離抗体 |
TW530054B (en) | 1997-09-24 | 2003-05-01 | Duphar Int Res | New piperazine and piperidine compounds |
SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
US6914058B2 (en) * | 2002-01-18 | 2005-07-05 | Dr. Reddy's Laboratories, Limited | Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them |
EP1501514B1 (en) | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
US7015227B2 (en) | 2002-06-21 | 2006-03-21 | Cgi Pharmaceuticals, Inc. | Certain amino-substituted monocycles as kinase modulators |
US20040067985A1 (en) | 2002-10-04 | 2004-04-08 | Fortuna Haviv | Method of inhibiting angiogenesis |
SE0203753D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
FR2850652B1 (fr) * | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
JP2007521252A (ja) | 2003-04-11 | 2007-08-02 | エスジーエックス ファーマシューティカルズ,インコーポレイティド | 化合物ライブラリーおよび薬剤発見方法 |
WO2005115985A1 (en) | 2004-05-27 | 2005-12-08 | Pfizer Limited | Aminopyridine derivatives as selective dopamine d3 agonists |
SA05260265A (ar) | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
CA2603959A1 (en) | 2005-04-08 | 2006-10-19 | Eisai R & D Management Co., Ltd. | Therapeutic agent for dyskinesia |
WO2007011760A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
GB0517175D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
PE20071241A1 (es) | 2006-01-17 | 2008-01-14 | Schering Corp | Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios |
US8895711B2 (en) | 2006-04-18 | 2014-11-25 | The Trustees Of The University Of Pennsylvania | Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP) |
WO2008002671A2 (en) | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
KR20090088852A (ko) | 2006-09-05 | 2009-08-20 | 메다렉스, 인코포레이티드 | 골형성 단백질의 항체와 이의 수용체 및 이의 사용방법 |
US20100093760A1 (en) | 2006-09-12 | 2010-04-15 | The General Hospital Corporation | Methods for identifying compounds that modulate cell signaling and methods employing such compounds |
UA97813C2 (uk) * | 2006-12-05 | 2012-03-26 | Янссен Фармацевтика Н.В. | Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу |
EP2265603B1 (en) | 2008-03-13 | 2014-05-07 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
WO2010008739A2 (en) | 2008-06-20 | 2010-01-21 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
CN103079585B (zh) | 2010-08-20 | 2015-09-30 | 惠氏有限责任公司 | 经设计的成骨蛋白 |
AU2011340167A1 (en) | 2010-12-06 | 2013-07-18 | Piramal Enterprises Limited | Substituted imidazoquinoline derivatives |
WO2012087938A1 (en) | 2010-12-20 | 2012-06-28 | Glaxosmithkline Llc | Quinazolinone derivatives as antiviral agents |
US8987271B2 (en) | 2010-12-22 | 2015-03-24 | Eutropics Pharmaceuticals, Inc. | 2,2′-biphenazine compounds and methods useful for treating disease |
BR112013029640A2 (pt) | 2011-05-23 | 2017-06-13 | Merck Patent Gmbh | derivados de piridina e pirazina |
TWI568714B (zh) | 2011-09-09 | 2017-02-01 | 藍瑟斯醫學影像公司 | 用於合成及使用造影劑之組合物、方法及系統 |
JP6430383B2 (ja) * | 2012-09-28 | 2018-11-28 | ヴァンダービルト ユニバーシティーVanderbilt University | 選択的bmp阻害剤としての縮合複素環化合物 |
US20160115167A1 (en) * | 2013-03-04 | 2016-04-28 | The Brigham And Women's Hospital, Inc. | Bmp inhibitors and methods of use thereof |
EP2970311A4 (en) | 2013-03-14 | 2016-11-23 | Brigham & Womens Hospital | BMP INHIBITORS AND METHODS OF USE |
ES2738493T3 (es) * | 2013-03-14 | 2020-01-23 | Tolero Pharmaceuticals Inc | Inhibidores de JAK2 y ALK2 y métodos para su uso |
PT3060550T (pt) | 2013-10-21 | 2019-08-27 | Merck Patent Gmbh | Compostos de heteroarilo como inibidores de btk e utilizações dos mesmos |
WO2015152183A1 (ja) | 2014-03-31 | 2015-10-08 | 大日本住友製薬株式会社 | 進行性骨化性線維異形成症の予防剤及び治療剤 |
CN107257793A (zh) | 2015-01-20 | 2017-10-17 | 梅里亚股份有限公司 | 抗蠕虫化合物、组合物及其使用方法 |
EA037520B1 (ru) | 2016-07-20 | 2021-04-07 | Новартис Аг | Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2 |
WO2018106820A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
-
2017
- 2017-07-18 EA EA201990343A patent/EA037520B1/ru unknown
- 2017-07-18 TW TW110101592A patent/TWI755255B/zh active
- 2017-07-18 EA EA202190285A patent/EA202190285A1/ru unknown
- 2017-07-18 AU AU2017298187A patent/AU2017298187B2/en active Active
- 2017-07-18 TW TW112118991A patent/TW202336011A/zh unknown
- 2017-07-18 CA CA3030332A patent/CA3030332A1/en active Pending
- 2017-07-18 EP EP21202619.9A patent/EP3971177A1/en active Pending
- 2017-07-18 TW TW111103316A patent/TWI806385B/zh active
- 2017-07-18 RS RS20211582A patent/RS62819B1/sr unknown
- 2017-07-18 PL PL17830463T patent/PL3487851T3/pl unknown
- 2017-07-18 KR KR1020227003660A patent/KR102454129B1/ko active IP Right Grant
- 2017-07-18 LT LTEPPCT/CN2017/093385T patent/LT3487851T/lt unknown
- 2017-07-18 BR BR112019000941-8A patent/BR112019000941A2/pt active Search and Examination
- 2017-07-18 SI SI201731040T patent/SI3487851T1/sl unknown
- 2017-07-18 MX MX2019000837A patent/MX2019000837A/es unknown
- 2017-07-18 HR HRP20211868TT patent/HRP20211868T1/hr unknown
- 2017-07-18 KR KR1020217022916A patent/KR102359707B1/ko active IP Right Grant
- 2017-07-18 CN CN202111145806.6A patent/CN114014844A/zh active Pending
- 2017-07-18 US US16/318,250 patent/US10710980B2/en active Active
- 2017-07-18 EP EP17830463.0A patent/EP3487851B1/en active Active
- 2017-07-18 TW TW106123900A patent/TWI712598B/zh active
- 2017-07-18 KR KR1020227034980A patent/KR102559539B1/ko active IP Right Grant
- 2017-07-18 WO PCT/CN2017/093385 patent/WO2018014829A1/en unknown
- 2017-07-18 ES ES17830463T patent/ES2902521T3/es active Active
- 2017-07-18 KR KR1020237024969A patent/KR20230117248A/ko active IP Right Grant
- 2017-07-18 DK DK17830463.0T patent/DK3487851T3/da active
- 2017-07-18 RU RU2019104609A patent/RU2747318C2/ru active
- 2017-07-18 CN CN201780044640.4A patent/CN109641871B/zh active Active
- 2017-07-18 JP JP2019502675A patent/JP7030776B2/ja active Active
- 2017-07-18 KR KR1020197004529A patent/KR102281550B1/ko active IP Right Grant
- 2017-07-18 HU HUE17830463A patent/HUE057328T2/hu unknown
- 2017-07-18 PT PT178304630T patent/PT3487851T/pt unknown
- 2017-07-19 UY UY0001037331A patent/UY37331A/es not_active Application Discontinuation
- 2017-07-20 AR ARP170102033A patent/AR109108A1/es unknown
-
2019
- 2019-01-18 MX MX2021014852A patent/MX2021014852A/es unknown
- 2019-10-10 AU AU2019246857A patent/AU2019246857B2/en active Active
-
2020
- 2020-05-27 US US16/884,666 patent/US10947218B2/en active Active
-
2021
- 2021-02-08 US US17/170,690 patent/US20210155606A1/en active Pending
- 2021-03-04 AU AU2021201424A patent/AU2021201424C1/en active Active
- 2021-12-29 CY CY20211101137T patent/CY1124967T1/el unknown
-
2022
- 2022-02-22 JP JP2022025894A patent/JP7253086B2/ja active Active
-
2023
- 2023-01-19 AU AU2023200265A patent/AU2023200265A1/en active Pending
- 2023-03-24 JP JP2023048083A patent/JP2023089012A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124959T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
CY1123595T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 | |
CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
CY1125436T1 (el) | Αναστολεις dna-pk | |
CY1124967T1 (el) | Παραγωγα αμινοπυριδινης και χρηση αυτων ως εκλεκτικοι αναστολεις alk-2 | |
CY1124068T1 (el) | Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6 | |
CY1120969T1 (el) | Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης | |
CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
CY1120903T1 (el) | Ενωσεις αμινοπυριδυλοξυπυραζολιου | |
CY1120361T1 (el) | Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido) | |
EA202091508A1 (ru) | 6-азаиндольные соединения | |
CY1122740T1 (el) | Ευτηκτικα σκευασματα υδροχλωρικης κυκλοβενζαπρινης και μαννιτολης | |
EA202091484A1 (ru) | 4-азаиндольные соединения | |
CY1124425T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης | |
CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
CY1123920T1 (el) | Αντιγριπικο πολυκυκλικο παραγωγο πυριδονης και προφαρμακο αυτου | |
CY1121550T1 (el) | Ενωσεις πυριδινης πλαδιενολιδης και μεθοδοι χρησης | |
EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
CR20170315A (es) | Inhibridores bace 1 selectivos | |
EA201692091A1 (ru) | Хиноксалиновые соединения и их применение | |
CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
EA202091477A1 (ru) | Замещенные соединения простых индольных эфиров | |
CY1122313T1 (el) | Ορβεπιταντη για την αγωγη του χρονιου κνησμου | |
CY1121345T1 (el) | Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης | |
EA201791992A1 (ru) | Ингибиторы грелин-o-ацилтрансферазы |